{
  "story_id": "af6f59be8c796b57bab72ae0c2f91ffc",
  "desk": "drm3",
  "revision": 2,
  "published_at": "2026-09-03T18:50:16.355Z",
  "content_hash": "20823e0e530ac30ee46ede6644d5b4ad54aada89134ddd6843c334b466494d54",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Moderna stock: intismeran data, valuation, and ESMO decide if 52-week high is reclaimed",
    "dek": "Moderna shares up 177% on intismeran success trade 18% below high ahead of ESMO data.",
    "prose": "On 2026-08-19, Moderna and Merck announced that intismeran, their personalized mRNA cancer vaccine, met its primary endpoint in a Phase 3 melanoma trial, making it the first mRNA-based cancer therapy to succeed at Phase 3. [^1]\n\nAs of 2026-09-03 at 2:33 PM EDT, Moderna's shares (NASDAQ: MRNA) traded at $144.83, about 18% below the 52-week high of $176.66. [^2] Following the trial announcement, Moderna's stock rallied approximately 177%, recovering from a roughly 90% decline during the COVID-era. [^3] Wall Street analysts project intismeran sales to exceed $1 billion by 2030 and $3 billion by 2035. [^4]\n\nEmerging evidence suggests that adapting radiotherapy to immunotherapy could offer new opportunities for treating localized pancreatic cancer. [^5] Pancreatic cancer is characterized by a unique tumor microenvironment that facilitates immune evasion and presents significant clinical challenges for treatment. [^6] Recent randomized phase 3 trials, such as PACT-21 CASSANDRA and PREOPANC-2, are evaluating neoadjuvant chemoradiotherapy versus chemotherapy or immunotherapy combinations for resectable and borderline resectable pancreatic cancer. [^7]\n\nThe American Cancer Society projects that cancer incidence and death rates in the US will continue to rise through 2040. [^8]",
    "cited": "[{\"statement\":\"On 2026-08-19, Moderna and Merck announced that intismeran, their personalized mRNA cancer vaccine, met its primary endpoint in a Phase 3 melanoma trial, making it the first mRNA-based cancer therapy to succeed at Phase 3.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T18:36:31.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"As of 2026-09-03 at 2:33 PM EDT, Moderna's shares (NASDAQ: MRNA) traded at $144.83, about 18% below the 52-week high of $176.66.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T18:36:31.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"Following the trial announcement, Moderna's stock rallied approximately 177%, recovering from a roughly 90% decline during the COVID-era.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T18:36:31.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"Wall Street analysts project intismeran sales to exceed $1 billion by 2030 and $3 billion by 2035.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T18:36:31.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"Emerging evidence suggests that adapting radiotherapy to immunotherapy could offer new opportunities for treating localized pancreatic cancer.\",\"source\":\"Nature\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T18:50:16.355Z\",\"publisher_count\":1,\"sources\":[\"Nature\"]},{\"statement\":\"Pancreatic cancer is characterized by a unique tumor microenvironment that facilitates immune evasion and presents significant clinical challenges for treatment.\",\"source\":\"Nature\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T18:50:16.355Z\",\"publisher_count\":1,\"sources\":[\"Nature\"]},{\"statement\":\"Recent randomized phase 3 trials, such as PACT-21 CASSANDRA and PREOPANC-2, are evaluating neoadjuvant chemoradiotherapy versus chemotherapy or immunotherapy combinations for resectable and borderline resectable pancreatic cancer.\",\"source\":\"Nature\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T18:50:16.355Z\",\"publisher_count\":1,\"sources\":[\"Nature\"]},{\"statement\":\"The American Cancer Society projects that cancer incidence and death rates in the US will continue to rise through 2040.\",\"source\":\"Nature\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-03T18:50:16.355Z\",\"publisher_count\":1,\"sources\":[\"Nature\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "f743c0e8a2210f3eda87772de4693350",
      "thread_id": "3287736ba9971b6c75d54003e6c690d7",
      "thread_label": "ESMO",
      "novelty": "UPDATE",
      "content_hash": "48a3e404b2ead86e892fe0be8dac39bbccfbba8ee4ab625ed354279b8bc837c8",
      "last_published_at": "2026-09-03T18:50:16.355Z",
      "read_receipt": {
        "slice_hash": "bc4a10dedbbb8e32a3e87e4061a6fd445333ee06d8400c32569c78e808b25e96",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDNUMTg6MTU6MTcuMDAwMDAwWiIsImlkIjoiOWY0MzJhMmYyNjlmNTA4NzUxNDBiZWQ2NGY2YzJiNmMiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDNUMTg6NTU6MTAuMDAwMDAwWiIsImlkIjoiM2NlYjM0MDMwNmM3ODA0NWE2YzM0NTBkODczMWRhYjAiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12166856,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "hJ-Uw96WHeLVmeBhal2vmAevzd_NCiZwtRg7sFI_sstKVZwjWE-nv0lm6QR-BjJhMqgOHBK9pMBPdXnniJWuAg",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      },
      "compose": 3,
      "recomposed_at": "2026-09-05T20:20:48.102Z"
    },
    "written_at": "2026-09-04T06:35:48.321Z"
  },
  "cited_facts": [
    {
      "n": 1,
      "statement": "On 2026-08-19, Moderna and Merck announced that intismeran, their personalized mRNA cancer vaccine, met its primary endpoint in a Phase 3 melanoma trial, making it the first mRNA-based cancer therapy to succeed at Phase 3.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 2,
      "statement": "As of 2026-09-03 at 2:33 PM EDT, Moderna's shares (NASDAQ: MRNA) traded at $144.83, about 18% below the 52-week high of $176.66.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 3,
      "statement": "Following the trial announcement, Moderna's stock rallied approximately 177%, recovering from a roughly 90% decline during the COVID-era.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 4,
      "statement": "Wall Street analysts project intismeran sales to exceed $1 billion by 2030 and $3 billion by 2035.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 5,
      "statement": "Emerging evidence suggests that adapting radiotherapy to immunotherapy could offer new opportunities for treating localized pancreatic cancer.",
      "source": "Nature",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 6,
      "statement": "Pancreatic cancer is characterized by a unique tumor microenvironment that facilitates immune evasion and presents significant clinical challenges for treatment.",
      "source": "Nature",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 7,
      "statement": "Recent randomized phase 3 trials, such as PACT-21 CASSANDRA and PREOPANC-2, are evaluating neoadjuvant chemoradiotherapy versus chemotherapy or immunotherapy combinations for resectable and borderline resectable pancreatic cancer.",
      "source": "Nature",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    },
    {
      "n": 8,
      "statement": "The American Cancer Society projects that cancer incidence and death rates in the US will continue to rise through 2040.",
      "source": "Nature",
      "instrument": "News",
      "claim_key": null,
      "url": null,
      "occurred_at": null,
      "published_at": null
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true. The dates on cited_facts (occurred_at, published_at) are the forge's, joined at read time; they are not part of the signed basis above."
}